Greg Cost, PhD

Before join­ing Metageno­mi, Greg was a Prin­ci­pal Sci­en­tist at Case­bia Ther­a­peu­tics, devel­op­ing new treat­ments for hema­to­log­i­cal and autoim­mune dis­or­ders using CRISPR-Cas9 gene edit­ing. Pri­or to Case­bia, Greg worked at Sang­amo Bio­Sciences for ten years, apply­ing zinc-fin­ger nucle­ase tech­nol­o­gy to engi­neer mam­malian genomes. Greg earned his Ph.D. from Johns Hop­kins Uni­ver­si­ty for work on human repet­i­tive DNA with Dr. Jef Boeke, before con­tin­u­ing his stud­ies at the Insti­tut Pas­teur in Paris. 

Greg was a Damon Run­y­on post­doc­tor­al fel­low study­ing DNA recom­bi­na­tion at UC Berke­ley with Dr. Nicholas Coz­zarel­li. He also holds a bachelor’s degree in Chem­istry from Xavier University.